Grange Capital LLC Takes Position in Alumis Inc. $ALMS

Grange Capital LLC purchased a new position in Alumis Inc. (NASDAQ:ALMS) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 32,000 shares of the company’s stock, valued at approximately $312,000.

A number of other hedge funds also recently bought and sold shares of the company. Russell Investments Group Ltd. grew its position in Alumis by 320.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 6,419 shares of the company’s stock valued at $26,000 after purchasing an additional 4,894 shares during the last quarter. New York State Common Retirement Fund raised its holdings in Alumis by 173.7% in the second quarter. New York State Common Retirement Fund now owns 11,767 shares of the company’s stock worth $35,000 after buying an additional 7,467 shares during the last quarter. CWM LLC lifted its stake in shares of Alumis by 1,028.7% in the third quarter. CWM LLC now owns 10,384 shares of the company’s stock worth $41,000 after buying an additional 9,464 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Alumis by 26.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,724 shares of the company’s stock worth $46,000 after buying an additional 979 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its holdings in shares of Alumis by 104.9% during the third quarter. BNP Paribas Financial Markets now owns 11,770 shares of the company’s stock valued at $47,000 after buying an additional 6,027 shares during the last quarter.

Alumis Stock Down 0.4%

Shares of Alumis stock opened at $23.66 on Friday. Alumis Inc. has a twelve month low of $2.76 and a twelve month high of $30.60. The company’s 50 day moving average is $25.09 and its 200 day moving average is $18.27. The company has a market cap of $3.01 billion, a price-to-earnings ratio of -7.73 and a beta of -0.31.

Alumis (NASDAQ:ALMS) last posted its earnings results on Thursday, March 19th. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.05). The company had revenue of $1.93 million during the quarter, compared to the consensus estimate of $2.75 million. Alumis had a negative return on equity of 116.97% and a negative net margin of 1,011.75%. Sell-side analysts expect that Alumis Inc. will post -3.06 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ALMS has been the subject of several analyst reports. Oppenheimer raised their price target on shares of Alumis from $50.00 to $55.00 and gave the company an “outperform” rating in a research report on Monday, March 30th. Stifel Nicolaus began coverage on Alumis in a research note on Wednesday, February 25th. They set a “buy” rating and a $44.00 target price on the stock. Raymond James Financial started coverage on Alumis in a report on Tuesday, March 10th. They issued a “strong-buy” rating and a $46.00 target price for the company. Loop Capital set a $37.00 price target on Alumis in a research note on Wednesday, January 21st. Finally, HC Wainwright lowered their price target on Alumis from $40.00 to $25.00 and set a “buy” rating on the stock in a report on Monday, March 30th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $38.60.

Alumis Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.